Patents Examined by Maria Marvich
  • Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
    Patent number: 10066215
    Abstract: Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: September 4, 2018
    Assignee: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kyuhyun Lee, Seongtae Yun, Daekyung Koh, Hong-Kyu Lee, Eui-Cheol Jo
  • Gene therapy vectors and cytosine deaminases
    Patent number: 10035983
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 31, 2018
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Induced regulatory T cell and use thereof
    Patent number: 10030226
    Abstract: The present invention relates to a transduced T cell precursor prepared by introducing a gene construct comprising a polynucleotide encoding C/EBP (CCAAT/enhancer binding protein) to a T cell precursor and overexpressing the C/EBP thereby, wherein the transduced T cell precursor is capable of differentiating into a regulatory T cell and an induced regulatory T cell differentiated therefrom. The transduced T cell precursor and the induced regulatory T cell may be useful for preventing and treating autoimmune diseases, inflammatory diseases and graft rejections caused by the malfunction of immune response.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: July 24, 2018
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Rho Hyun Seong, Sung Kyu Lee
  • Oncolytic adenoviruses for cancer treatment
    Patent number: 10016470
    Abstract: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: July 10, 2018
    Assignee: DNATRIX, INC.
    Inventors: Ramon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
  • Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein
    Patent number: 10017784
    Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: July 10, 2018
    Assignee: ID PHARMA CO., LTD.
    Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
  • Method for cell culture
    Patent number: 10011816
    Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: July 3, 2018
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
  • Method of targeting gene delivery using viral vectors
    Patent number: 9994867
    Abstract: Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: June 12, 2018
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David Baltimore, Pin Wang, Lili Yang
  • Constructs for gene expression analysis
    Patent number: 9994858
    Abstract: The present invention relates generally to constructs and their use in gene expression or gene regulation assays. More particularly, the present invention provides expression vectors and/or reporter vectors providing kinetics of protein expression with improved temporal correlation to promoter activity. Even more particularly, the invention provides expression vectors comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding a RNA element that modulates the stability of a transcript corresponding to the transcribable polynucleotide. The present invention provides, inter alia, novel vectors, useful for identifying and analysing cis- and trans-acting regulatory sequences/factors as well as vectors and genetically modified cell lines or organisms that are particularly useful for drug screening and drug discovery.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: June 12, 2018
    Assignee: Gene Stream PTY LTD
    Inventor: John Daly
  • Method for cell culture
    Patent number: 9976117
    Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: May 22, 2018
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
  • Administration of kynurenine depleting enzymes for tumor therapy
    Patent number: 9975959
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: May 22, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Nicholas Marshall, John Blazeck, Wei-Cheng Lu
  • Methods of DNA constructs for high yield production of polypeptides
    Patent number: 9951368
    Abstract: The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: April 24, 2018
    Assignee: Medtronic, Inc.
    Inventors: James A. Williams, Peng Luan, Yuannan Xia, Scott Harley
  • Methods of preparing cells and compositions
    Patent number: 9951350
    Abstract: The present invention provides a method of preparing adult red blood cells from stem cells in vitro using certain transcription factors for use in medicine, transfusions and transplants. The invention also provides blood compositions with cells prepared by the method.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: April 24, 2018
    Assignee: NHS Blood & Transplant
    Inventors: Jan Frayne, David Anstee
  • Method for cell culture
    Patent number: 9944895
    Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: April 17, 2018
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
  • Methods of modifying a target nucleic acid with an argonaute
    Patent number: 9902973
    Abstract: This disclosure provides for compositions and methods for the use of designed nucleic acid-targeting nucleic acids, Argonautes, and complexes thereof.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: February 27, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: John Van Der Oost, Daniël Christianus Swarts, Andrew Paul May, Rachel E. Haurwitz
  • Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells
    Patent number: 9890357
    Abstract: The present invention provides a method for inducing differentiation of a human pluripotent stem cell into an intermediate mesoderm cell without the use of a growth factor. Such method comprises performing culture in a medium containing a specific compound, so as to induce differentiation of a human pluripotent stem cell into an intermediate mesoderm cell.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: February 13, 2018
    Assignee: KYOTO UNIVERSITY
    Inventors: Kenji Osafune, Toshikazu Araoka
  • Method for modulating resistance
    Patent number: 9879269
    Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: January 30, 2018
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Rodolphe Barrangou, Patrick Boyaval, Philippe Horvath, Christophe Fremaux, Dennis A. Romero
  • Culture medium for cell growth and transfection
    Patent number: 9879243
    Abstract: The present invention is directed generally to cell culture media useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells) in the presence of said media. Cells containing introduced materials can be further cultured in the media. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention thus provides efficient and high throughput methods to transform/transfect culture and cells avoiding the need for multiple manipulations and transfers of cells during transfection and expression studies.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: January 30, 2018
    Assignee: LifeTechnologies Corporation
    Inventors: Valentina C. Ciccarone, Dale Gruber, Shelly Bennett
  • Hybrid caulimovirus promoters and constructs thereof
    Patent number: 9856491
    Abstract: The present invention relates to novel hybrid promoters comprising a caulimovirus promoter operably linked to one or more of an EF1?, Act8, Act2 or Act11 promoter. The present invention also relates to novel DNA constructs comprising at least one expression cassette which comprises the hybrid promoter thereof. The present invention further relates to transgenic plants/seeds comprising such DNA constructs.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 2, 2018
    Assignee: Monsanto Technology LLC
    Inventors: Karen L. Fincher, Stanislaw Flasinski, Jack Q. Wilkinson
  • Minimal vectors for genome integration
    Patent number: 9840718
    Abstract: Disclosed are genetic delivery systems that utilize genetic elements of the piggyBac family transposon system, and methods of introducing nucleic acid into target cells using the genetic delivery systems.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: December 12, 2017
    Assignee: University of South Alabama
    Inventors: Victor Solodushko, Brian Fouty, Vira Bitko
  • Transgenic microalgae and use thereof for oral delivery of proteins
    Patent number: 9827280
    Abstract: Transgenic microalgae expressing at least one exogenous biologically active protein. The protein-expressing microalgae are used for the oral delivery of the biologically active protein to the target organism in its intact and functional form. The exogenous protein, expressed in algae, is characterized by being biologically active, exerting at least one specific activity having a beneficial effect on the subject consuming the algae. The transgenic microalgae are used as animal food for aquatic or land animals welfare or as food supplement for human healthcare.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: November 28, 2017
    Assignee: TRANSALGAE ISRAEL LTD.
    Inventors: Shiri Moshitzky, Doron Eisenstadt, Guy Levi, Ofra Chen